PHARMACOVIGILANCE APPROVAL

Pharmacovigilance System Approval

ACS Canada provides Pharmacovigilance System Approval services for pharmaceutical manufacturers, distributors, importers, marketing authorization holders, healthcare organizations, clinical research organizations, and related pharmaceutical service providers.

Pharmacovigilance (PV) is the science and practice of detecting, assessing, understanding, and preventing adverse effects and other medicine-related problems. An effective Pharmacovigilance System supports patient safety, regulatory compliance, product quality, and continual monitoring of medicinal products throughout their lifecycle.

ACS Canada conducts independent assessments of pharmacovigilance systems against internationally recognized pharmaceutical industry practices, regulatory expectations, and risk management principles to verify the effectiveness of adverse event reporting, safety monitoring, signal detection, and corrective action processes.

Scope of Pharmacovigilance System Approval

• Adverse Event (AE) and Adverse Drug Reaction (ADR) reporting systems
• Safety data collection and management processes
• Signal detection and safety monitoring activities
• Risk management and benefit-risk evaluation procedures
• Pharmacovigilance documentation and record control
• Complaint handling and product safety investigations
• Corrective and preventive action (CAPA) management
• Pharmacovigilance training and competency programs
• Periodic safety review and reporting processes
• Supplier and service provider oversight related to PV activities

Key Elements Evaluated During Approval

• Pharmacovigilance policies and procedures
• Roles, responsibilities, and accountability
• Safety information collection and reporting timelines
• Data integrity and confidentiality controls
• Risk assessment and escalation processes
• Internal audits and management review activities
• Continuous improvement of patient safety systems

Benefits of Pharmacovigilance System Approval

• Demonstrates commitment to patient safety and public health
• Strengthens medicine safety monitoring programs
• Enhances confidence among regulators, healthcare providers, and stakeholders
• Improves adverse event reporting and risk management processes
• Supports pharmaceutical quality and compliance objectives
• Provides independent recognition of pharmacovigilance practices
• Reduces risks associated with medicine safety issues
• Promotes continual improvement of safety monitoring systems

Suitable Organizations

• Pharmaceutical manufacturers
• Marketing Authorization Holders (MAHs)
• Pharmaceutical importers and distributors
• Clinical research organizations (CROs)
• Biotechnology companies
• Healthcare organizations and hospitals
• Contract manufacturing organizations (CMOs)
• Pharmaceutical service providers